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Abstract
Data from a multi-parametric MRI study of patients with possible early-stage
prostate cancer was assessed with a view to creating an efficient clinical proto-
col. Based on a correlation analysis suggesting that diffusion-weighted imaging
(DWI) scores are more strongly correlated with overall PIRADS scores than
other modalities such as dynamic contrast enhanced imaging or spectroscopy,
we investigate the combination of T2-weighted imaging (T2w) and DWI as a
potential diagnostic tool for prostate cancer detection, staging and guided biop-
sies. Quantification of the noise floor in the DWI images and careful fitting of
the data suggests that the mono-exponential model provides a very good fit to
the data and there is no evidence of non-Gaussian diffusion for b-values up to
1000 s/mm2. This precludes the use of kurtosis or other non-Gaussian measures
as a biomarker for prostate cancer in our case. However, the ADC scores for
healthy and probably malignant regions are significantly lower for the latter in
all 20 but one patient. The results suggest that a simplified mp-MRI proto-
col combining T2w and DWI may be a good compromise for a cost and time
efficient, early-stage prostate cancer diagnostic programme, combining robust
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MR biomarkers for prostate cancer that can be reliably quantified and appear
well-suited for general clinical practice.
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1. Introduction
Prostate cancer is the second most common cancer in men worldwide [1].
For most developed countries there has been a decrease in death rates mainly
due to earlier diagnosis combined with better staging and treatment [2, 3]. The
diagnostic pathway has been driven by the use of serum prostate specific antigen
(PSA) testing with subsequent transrectal ultrasound (TRUS) scan and prostate
biopsies. However, the positive predictive value of a raised PSA and subsequent
TRUS guided biopsies is low [4], which leads to a considerable number of men
undergoing unnecessary biopsies and a marked increase in the detection of clin-
ically insignificant cancer [5]. This has significant cost implications and exposes
patients to the inherent risk of biopsy and treatment [6].
Diffusion-weighted imaging (DWI) is a functional magnetic resonance imag-
ing (MRI) technique that takes advantage of the diffusion of water molecules in
tissue to obtain information about tissue microstructure by calculating quan-
tities such as apparent diffusion coefficient (ADC), which have been shown to
be inversely correlated with increased cellularity in different tumor types [7].
DWI has shown potential in differentiating malignant from benign prostate tis-
sue, but it is usually used in combination with T2-weighted imaging (T2w) and
other MRI techniques for diagnostic purposes. Tissues with restricted diffusion
tend to also have lower signal on T2w images [8]. The combination with T2w
and advanced MRI techniques such as DWI, dynamic contrast enhanced imaging
(DCE) and spectroscopy (MRS), known as multi-parametric MRI (mp-MRI),
can improve diagnosis and staging for the peripheral prostate zone [9].
The aim of mp-MRI is three-fold: Potentially avoid prostate biopsies when
these are unnecessary; Target biopsies particularly in men who have previously
undergone a negative transrectal ultrasound scan and prostate biopsy and fi-
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nally to stage the disease in line with National Institute For Health and Clinical
Excellence (NICE) guidelines [10] when patients have been diagnosed and enter-
ing an active surveillance protocol. In addition there is some evidence to suggest
that these advanced MR techniques are useful in detection of low volume low
grade prostate cancers that require no active treatment and are often perceived
as being over diagnosis [11]. There is also the prospect of cancer localization in
patients with elevated PSA who have several negative biopsies [12, 13, 14] using
the greater anatomic information provided by mp-MRI. To standardize report-
ing of mp-MRI findings and reduce variability, a global system for the assessment
and reporting of prostate cancer (PIRADS) was proposed [15], combining T2w,
DWI, DCE and MRS, although MRS (alongside with other techniques) was
excluded in the latest version (PIRADS v2), but may be incorporated in later
versions [16]. Motivated by a statistical analysis of existing patient data showing
strong correlation of DWI and overall PIRADS scores, we analyse the robust-
ness of DWI-based biomarkers and their utility in improving the assessment and
management of patients with suspected early-stage prostate cancer.
2. Materials and methods
2.1. Patient population
From a cohort of patients participating in a early-stage prostate cancer as-
sessment examination, data of 46 acquired between 22/02/2015 and 24/08/2016,
were selected to evaluate the robustness and utility of advanced MRI tech-
niques. Patients were selected on three clinical criteria: (a) suitability for an
active surveillance programme, (b) patients with rising PSA in whom biopsy
seemed to be high risk, e.g., anti-coagulated patients and (c) patients with ris-
ing PSA who were unable to undergo biopsy for other clinical reasons such as
abdominoperineal resection. The patients were between 48 and 85 years old
with a mean age of 68. The study was funded by the Swansea Prostate Can-
cer Research Fund, ethical approval for the analysis of the data was obtained
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and the study was reviewed favourably by the institution’s Joint Scientific and
Research Committee.
2.2. MR protocol
In accordance with the original PIRADS (v1) protocol [15], the examina-
tions included T2w, MRS, DWI and DCE performed on a 3-Tesla MR scanner
(Siemens 3T Magnetom Skyra) using a 18-channel pelvic phased-array receive
coil. T2w imaging was performed in transverse, sagittal and coronal planes.
T2w images were acquired using a fast spin echo (FSE) sequence with the fol-
lowing parameters: TR: 4320 ms, TE: 101 ms, field of view (FOV): 256×256mm,
acquisition matrix: 320 × 320, flip angle: 160◦, slice thickness: 3mm, number
of averages: 3. DWI images were acquired using transverse echo planar imag-
ing (EPI), TR: 3800 ms, TE: 64 ms, FOV: 256 × 256mm, acquisition matrix:
128 × 128, flip angle: 90◦, slice thickness: 3 mm, number of averages: 8; b-
values: 0, 100, 800 and 1000 s/mm2.
2.3. Data analysis
The MR images were assessed by an experienced radiologist. 26 of the
patients selected were considered to have no abnormalities or benign conditions
e.g. benign prostatic hyperplasia. For the remaining 20 patients with suspected
cancer, the radiologist delineated suspicious and normal regions using custom-
shaped regions of interest (ROIs) based on the T2w images. The same ROIs
were applied to the ADC data sets after conversion to adjust for differences
in image resolution. Post-processing and calculations were performed using in-
house code written in MATLAB.
To assess background noise levels for the signal-to-noise (SNR) analysis in
the diffusion-weighted images, a ROI above the patient’s abdomen was selected.
It was not possible to place a ROI for every patient due to artifacts in some
of the images that made it impossible to select a suitable ROI in the air-only
region above the patient’s abdomen. To evaluate the level and variability of the
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noise for different slices and b-values, the mean signal intensity was computed
for all slices and b-values for 28 patients.
ADCs for the normal and suspicious regions were calculated by applying
a least squares linear fit of the logarithm of the signal S as a function of the
b-value according to
lnS = lnS0 − bD, (1)
where S0 is the signal at b = 0 and D is the ADC.
The same fitting routine was used to calculate ADCs for each voxel inside
the prostate for all 46 patients and to generate ADC maps. To visualize the
signal decay as a function of b-value for all voxels inside the prostate and as-
sess its linearity on a logarithmic scale, 3D waterfall plots were generated. To
elucidate the distribution of ADC values inside the prostate, ADC histograms
were computed by placing the data in bins of 50 mm2/s. The quality of each fit
for both single voxel and mean ROI signal fits was assessed by calculating R2,
the square of the correlation between the response values yˆi and the predicted
response values y¯i. R
2 is a measure of how well the fit models the variation in
the data. It is defined as the ratio of the sum of squares of the regression (SSR)
and the total sum of squares (SST)
R2 =
ESSR
ESST = 1−
ESSE
ESST , (2)
where ESSR is defined as
ESSR =
n∑
i=1
wi(yˆi − y¯)2, (3)
and ESST is the sum of squares about the mean
ESST =
n∑
i=1
wi(yi − y¯)2. (4)
ESSE is the sum of squares due to error and ESST = ESSR + ESSE. R2 can
take on values between 0 and 1. A value closer to 1 is indicative of a greater
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Total T2 DWI MRS DCE
Total 1 0.7633 0.8685 0.6540 0.7294
T2 1 0.6477 0.4724 0.3091
DWI 1 0.3474 0.5686
MRS 1 0.2354
DCE 1
Table 1: Correlation of T2w, DWI, MRS and DCE PIRADS scores with total PIRADS
scores. DWI appears to be most reliably correlated with the overall PIRADS scores, whereas
the correlation for the MRS scores is approximately 65%.
proportion of variance accounted for by the model.
The PIRADS scoring was performed by the same experienced radiologist
by evaluating the data for each technique and assigning a value between 1 and
5 according to the level of significance. The overall PIRADS score indicates
the probability of malignancy on imaging criteria. To assess the correlation of
PIRADS scores for different MR techniques and overall PIRADS scores, and
quantify the potential prognostic value of each technique with reference to the
overall PIRADS score, Pearson correlation coefficients between −1 and +1 were
computed, +1 indicating perfect positive, −1 perfect negative and 0 no linear
correlation [16, 17].
3. Results
3.1. Correlation of PIRADS Component Scores vs Total Scores
The Pearson correlation coefficients for the component and overall PIRADS
scores in Table 1) show that the scores for T2w and DWI correlate more strongly
with the overall PIRADS scores compared to those for MRS and DCE imag-
ing. Specifically, the DWI component scores and overall PIRADS scores have a
Pearson score of 87%, whereas MRS does not exceed 66%. Interestingly, there
is almost no correlation between T2w and MRS or DCE. The lack of correlation
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P 41 P 42 P 51 P 55 P 59 P 65 P 76
6.0 ±1.3 4.3 ±1.2 5.6 ±0.6 4.6 ±0.6 5.3 ±0.5 6.0 ±0.2 5.8 ±0.3
P106 P107 P108 P109 P110 P114 P116
5.1 ±0.3 5.1 ±0.3 5.0 ±0.3 5.1 ±0.4 5.4 ±0.5 5.6 ±0.3 5.3 ±0.5
P117 P119 P120 P124 P127 P129 P130
5.6 ±0.4 4.3 ±1.0 4.7 ±0.3 6.0 ±1.2 5.1 ±0.8 5.2 ±0.4 5.8 ±0.3
P131 P132 P133 P134 P136 P137 P139
5.4 ±0.3 6.1 ±1.2 5.4 ±0.8 5.0 ±0.4 5.7 ±0.5 6.3 ±0.6 5.9 ±1.2
Table 2: Noise statistics (mean/std) for selected patients
(a) (b)
Figure 1: (a) Noise stem plot showing mean noise level for each slice and b-value for one
patient. The mean noise over ROI does not vary significantly with slice and b-value. (b)
Corresponding histogram with indication of mean and standard deviation of noise.
with the overall PIRADS score, suggests that, in this cohort at least, it does
not add diagnostic value.
3.2. A posteriori background noise analysis
Noise levels were fairly low with the mean signal intensity in the noise ROIs
exceeding 6 (in arbitrary units) for only a few points (Table 1). A typical noise
stem plot and noise distribution histogram is shown in Fig. 1. Fig. 1 (a) shows
the noise level for each slice for four different b-values in different colors. We
observe that the noise levels do not vary significantly with slice position and
b-value as expected. Fig. 1 (b) shows that the background noise level is more
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(a) (b)
Figure 2: (a): T2w image of a selected patient within the prostate (green), the suspicious (red)
and contralateral (blue) normal areas delineated. (b): These ROIs were applied to the same
slice of the ADC map, in addition to a triangular ROI (top left red) for the noise analysis.
or less normally distributed around a mean value (red dashed line).
Based on the resulting estimates for the noise level, the threshold for sig-
nificance was set to 10, i.e., any points with signal intensity below 10 were
excluded from fits. For the purposes of reporting by the radiologist, the ADC
maps generated by the scanner software were used.
3.3. ADC Maps, Distribution of ADC values & Quality of Fit
ADC maps were computed for all patients and all slices. An example of a
typical ADC map is shown in Fig. 3 (a). A typical distribution of ADC values
for voxels inside the prostate is shown in Fig. 4 (b). The respective histogram
of the corresponding correlation coefficient R2 (Fig. 4 (b)) shows that R2 is
≥ 0.95 for almost all voxels, suggesting that the linear monoexponential decay
model provides a good fit for the data. The linearity of the signal decay for all
voxels is further evidenced by 3D waterfall plots, a typical example of which
is shown in Fig. 3 (b). The plot clearly shows that the logarithm of a signal
intensity varies linearly with b for the range of values 0 s/mm2 to 1000 s/mm2
for all voxels, i.e., we observe no evidence of non-Gaussian diffusion. This is
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(a) (b)
Figure 3: (a): ADC map for a delineated prostate. (b): Signal vs b-values waterfall plot
showing that the signal is well above the background noise level for all voxels and b-values
and the signal decay on a logarithm scale is linear.
(a) (b)
Figure 4: (a): Distribution of ADC values for one slice of a prostate. The distribution is
approximately symmetric around 1577mm2/s. (b): Distribution of R2 values.
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(a) (b)
Figure 5: (a): b-value to signal intensity semi-logarithmic plot. The linear ADC fit is indicative
of no kurtosis for both suspicious and normal delineated regions. (b): Normal (blue) Vs
Suspicious (red) ADC scatter plot, confirms that normal regions have higher ADC values
than suspicious ones. The error bars are relatively high for the suspicious regions which
corresponds to higher variation of the diffusion in this area.
not too surprising as usually a minimum b-value of 1500 s/mm2 is required to
quantify non-Gaussianity [18]. In the waterfall plots brighter colors (yellow)
indicate higher signal and darker colors (blue) lower signal.
3.4. ADC values for normal and suspicious ROI for patients
Fig. 5 shows a typical signal vs b-value plots for a normal and a suspicious
ROI for a patient with suspected cancer. The signal decays faster, i.e., the ADC
is higher, in the normal region. In both cases the linear fit is excellent, the signal
remains well above the noise floor for all b-values and the variation of the signal
over the respective ROI is small. Table 3 shows the ADC for the normal and
suspicious regions for the 20 patients with suspected cancer, showing that the
ADC for the suspicious ROIs is lower than the value for the normal ROI except
for one outlier.
4. Discussion
The combination of advanced MR techniques (mp-MRI) has become a use-
ful tool in the management of patients at risk of or diagnosed with prostate
10
ADC (mm2/s)
Patient Suspicious ROIs Normal ROIs
P015 731 (699, 762) 1821 (1511, 2132)
P038 1114 (919, 1309) 1686 (1336, 2036)
P041 1342 (971, 1714) 1233 (993, 1473)
P048 807 (658, 955) 1434 (1175, 1692)
P051 1065 (777, 1354) 1602 (1445, 1760)
P059 1373 (745, 2000) 1680 (1590, 1770)
P090 1434 (1245, 1623) 1761 (1565, 1917)
P094 1081 (862, 1301) 1447 (1236, 1658)
P095 1066 (949, 1183) 1334 (1054, 1614)
P099 1228 (934, 1522) 1385 (1054, 1614)
P105 1109 (866, 1353) 2004 (1688, 2339)
P110a 1592 (1427, 1632) 2020 (1910, 2129)
P110b 1566 (1394, 1738) 1754 (1578, 1930)
P112 1508 (1000, 2016) 2091 (1812, 2369)
P113 1811 (1589, 2033) 2230 (1989, 2472)
P118 1313 (1010, 1616) 1581 (1346, 1817)
P119 984 (851, 1118) 1594 (1346, 1842)
P120 1490 (1331, 1649) 1962 (1797, 2126)
P129 944 (723, 1164) 2137 (1913, 2361)
P134 1276 (1157, 1395) 2045 (1656, 2434)
P139 1622 (1173, 2072) 1902 (1715, 2089)
Table 3: Mean ADC with 95% confidence intervals for 20 patients with suspected malignancies.
11
cancer [19]. It is highly important for staging and has the potential to assist
therapy guidance in the future [20]. According to Ahmed et al. [11] prostate
biopsies could be avoided by a large proportion of men if mp-MRI was applied
for screening. Isebaert et al. [21] showed that the combination of T2w, DWI
and DCE increased sensitivity. Tan et al. [22] reported that DCE combined
with T2w improved prostate cancer detection but Hansford et al. [23] demon-
strated low differentiating value between cancerous and healthy regions in the
prostate especially in early-stage cancers. Our result suggest that DWI has the
highest correlation with overall PIRADS scores and our preliminary data on
DWI combined with T2w imaging in a cohort of patients selected for mp-MRI
screening gives promising results in terms of discrimination between normal and
suspicious tissue. This raises the possibility of tailoring mp-MRI protocols for
screening purposes. Dropping DCE and MRS significantly reduces the overall
examination time, in our case from 55 to 25 minutes, resulting in considerable
cost savings, improved patient experience and elimination of potential short and
long-term risks associated with exposure to gadolinium-based contrast agents
[24].
Except for one, all probably malignant cases (based on PIRADS scoring) had
higher ADC values for suspicious ROIs than respective normal ROIs (Fig.2), in
line with previous studies [25, 26, 27]. The ADC of the suspicious ROIs ranged
from 944 mm2/s to 1811 mm2/s (mean±std 1448±272 mm2/s) and those of the
normal ROIs ranged from 1514 mm2/s to 2230 mm2/s (mean±std 1910±229 mm2/s).
The error bars for the suspicious regions are significantly larger than the respec-
tive normal ones, indicative of more variation in the diffusion values and ADCs
in these regions. The wide range of values obtained (for patients P113 and P119
it is almost twice as much for the suspicious regions) is consistent with other
studies, e.g., Litjens et al. [28] reporting similar variation in the peripheral
zone of the prostate. Using b-values up to 2000 mm2/s and an endorectal coil
in addition to pelvic phased-array coil, Lemke et a. [29] have shown higher
kurtosis (K), as defined by the signal equation: ln(S/S0) = −bD(2) + b2D2(2)K,
lower ADC and diffusion coefficient (D(2)) values for the malignant regions in
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comparison to healthy ones. Similar results for both variables have also been
demonstrated in [30] using high b-values and a pelvic coil only. Sensitivity and
contrast between malignant and healthy areas were higher when assessing using
K or D(2) in compared to the ADC. These studies suggest that DWI with higher
b-values may be clinically more advantageous, in line with PIRADS (v2), which
suggests maximum b-values of 1400 s/mm2 or greater. While we see no evidence
of kurtosis in our patient cohort with maximum b-values of 1000 mm2/s, kurtosis
may observable for such high b-values.
Accurate quantification of the rectified noise floor is critical to avoid spuri-
ous kurtosis results when fitting diffusion signals, especially for high b-values.
A good signal-to-noise ratio provides information about the quality of an image
and is vital part of the quality assurance of an MRI system [31] but simple SNR
estimation may not be sufficient to avoid inadvertent noise floor fitting that
can result in inaccurate ADC values and spurious kurtosis. Quantification of
the background noise level was in some cases compromised by image artifacts,
aliasing effects or too small a FOV to place a suitable ROI, but in most cases
estimation of the (rectified) noise floor was possible by selecting a suitable ROI
as shown in Fig. 2. The results presented in Table 1 indicate that the level of
background noise for different patients is relatively constant, provided the same
protocol and coils are used, as expected. The noise level for acquisitions with
b = 0 was slightly greater than for higher b-value images due to overall increased
signal strength in the former case, but the differences were insignificant. Simi-
larly, there was little variation of the noise level for different slices and the overall
distribution of the background noise level for all slices and b-values followed a
normal distribution with small variance. In our case the maximum value of the
noise level observed was 7.3 and setting the threshold of significance to 10, i.e.,
discarding any data points with signal values below 10, appeared sufficient to
avoid noise-floor fitting effects for normal and suspicious region fits as well as
single voxel fits.
The single voxel analysis further enables studying the distribution of the
ADC values within the whole prostatic region, producing ADC maps (Fig. 3 (a))
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and histograms that can aid clinical diagnosis by comparing the ADC values for a
suspicious region with the overall distribution for a particular patient. Although
the range of ADC values for different patients is subject to variation we observe
significant uniformity in the distribution of ADC for each patient, as shown in
Fig. 4 (a) for example. We also assessed the quality of the linear regression
fits. The vast majority of our data resulted in fits with R2 values very close
to 1 (Fig. 4 (b), for example) suggesting that the data are well explained by a
monoexponential Gaussian diffusion model. The linearity of signal decay, i.e.,
absence of evidence of kurtosis, is further exemplified in waterfall plots of the
logarithm of the signal vs b-value for all voxels, as shown in Fig.3 (b). As the
lowest ADC values for all b-values are significantly higher than the noise floor
there should be no contamination of the signal by the noise floor even for high
b-values.
This study is limited by small numbers and lack of histopathological corre-
lation with the mp-MRI finding. Not all patients went on to have a targeted
biopsy, which would have allowed us to confirm whether any areas of concern
were cancer or not. We currently have funding for an extension of this study
for a cohort of patients with a raised PSA and/or abnormal digital rectal exam-
ination who will have biopsies of the prostate with targeting of any abnormal
areas based on mp-MRI to answer to this important question. In addition there
is a limited range of b-values used for DWI. We would expect to find evidence
of non-Gaussian diffusion at higher b-values and further study of the effect of
the rectified noise floor on the reliability of non-linear regression fits for high
b-values would be desirable.
5. Conclusions
Although further studies with a larger patient cohort are required to assess
the reliability of T2w and DWI alone for early-stage prostate cancer screening
examinations, our preliminary results suggest that DWI combined with T2w
could be a useful clinical tool for prostate cancer assessment and management.
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It could improve the efficiency of MRI-based screening protocols, reducing scan
times and facilitating reporting by radiologists, especially when combined with
artificial intelligence.
Our finding that DCE results correlated poorly with overall PIRADS scores
and demonstrated no added value in this study may be due to DCE character-
istics being mostly of value in the assessment and staging of more advanced and
larger tumors. Though not the subject of this paper, the same likely applies to
MRS. The limited spatial resolution and partial volume effects combined with
overall noisy spectra make it difficult to detect spectroscopic biomarkers for
prostate cancer for early-stage, small volume lesions. MRS is likely to be more
useful in the assessment of larger tumors.
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